Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Amneal Takes A Step Forward On Biosimilars

FDA Accepts Filing For Bevacizumab Rival To Avastin, Partnered With Mabxience

Executive Summary

The FDA’s acceptance of Amneal’s filing for bevacizumab brings the company a step closer to its goal of launching a US biosimilar every year to 2023.

You may also be interested in...



Baclofen Deal Offers Amneal Biosimilars Advantage

Amneal says an $83.5m deal to acquire Saol Therapeutics’ baclofen franchise will also bring the firm an “experienced institutional commercial team” that will be able to support three biosimilar launches that the company now expects to execute in 2022.

Apotex Begins Roll Out Of Avastin Biosimilar In Canada

Following recent Health Canada approval, Apotex has launched partner mAbxience’s Bambevi (bevacizumab) biosimilar across Canada, adding to its portfolio of biosimilars that includes both filgrastim and pegfilgrastim.

Amneal Plans ‘Meaningful Additions’ To Its Generics Portfolio

Amneal continues to focus on new generics launches as the company sees its quarterly and half-yearly revenues increase on the back of its new launches and generics portfolio. The US-based company said that it was looking to continue its shift towards complex generics, as it considers eventually building in-house capabilities for biosimilars.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB151013

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel